Seeking Alpha

Brian Marckx, CFA

 
View as an RSS Feed
View Brian Marckx, CFA's Articles BY TICKER:
  • CombiMatrix Turns In Another Record Quarter, Stock Remains Undervalued
    Mon, Aug. 11 CBMX 2 Comments

    Summary

    • Another record quarter with fundamentals remaining very strong.
    • Stock price may be reacting negatively to litigation expense. We think investors should focus on strong operational performance.
    • Management continues to deliver on strategy focused on growth of prenatal microarray platform which generates highest revenue per test and holds most potential for long-term growth.
    • Recent investments in sales force and billing/reimbursement department are already paying dividends.
    • We think the stock remains undervalued.
  • Protea Biosciences' LAESI Technology Revolutionizing Mass Spectrometry
     • Sat, Aug. 2 PRGB Comment!

    Summary

    • Protea is at the initial stages of the roll-out of its LAESI technology which is used with mass spectrometry and appears to have substantive advantages over traditional ionization methods.
    • Seven units have been sold but expect the placement curve to steepen, facilitated by greater awareness of the technology in medical research and the recent hiring of key sales personnel.
    • Distribution agreement also in place with Waters Corp, additional distribution deals could be penned with other mass spec manufacturers in the near term.
    • Commercialization of the LAESI instruments is being complemented with the company’s molecular information services offerings and collaborations with leading medical institutions and industry partners.
    • These partnerships and collaborations are expected to help build awareness of LAESI and Protea’s capabilities and eventually lead to new product launches and services offerings.
  • Cardiac Surgery Rapidly Evolving As Substantial Opportunity For CytoSorbents
       • Sat, Jul. 19 CTSO 20 Comments

    Summary

    • Cardiac Surgery A New Major Focus for CytoSorbents.
    • Additional Data Supports Use of CytoSorb in Cardiac Surgery.
    • Expect Cardiac Surgery Will Be Initial U.S. Indication.
  • CombiMatrix Exploiting Growth Of Chromosomal Microarray For Prenatal Analysis
       • Thu, Jul. 10 SQNM, CBMX 14 Comments

    Summary

    • Molecular diagnostics company CBMX has offered a variety of genetic tests for various indications but just recently shifted the majority of its focus for growth on chromosomal microarray analysis.
    • Chromosomal microarray has gained more attention due to two recent NEJM-published studies and a recommendation from an influential trade association supporting its use in prenatal analysis.
    • CBMX is positioning itself to exploit an industry shift away from the current standard testing method towards CMA by expanding distribution, entering into key partnerships and leveraging competitive advantages.
  • LED Medical: Seasoned Executives Positioning Company For Industry Leadership
    Tue, Jul. 1 LEDIF 1 Comment

    Summary

    • LED Medical has strengthened its team with the recent appointments of Dr. David Gane and Lamar Roberts to key executive positions.
    • Gane and Roberts have led the execution of several new partnerships and initiatives for LED Medical.
    • Leadership is quickly evolving LED Medical from a product line manufacturer to a comprehensive supplier of digital imaging technologies to the North American dental market.
  • Medgenics Looking To Exploit Orphan Drug Market With Its Novel Biopump Protein Therapy Technology
       • Wed, Jun. 11 MDGN 4 Comments

    Summary

    • Biopump offers an innovative method of producing and delivering therapeutic proteins or peptides through the use of a patient's own skin.
    • Biopump offers potentially significant advantages over traditional intravenous protein therapy.
    • In September 2013, the company brought on new executive management with a specific goal of accelerating development of the Biopump technology, with a particular emphasis on orphan diseases.
    • Biopump will be further validated in just-commenced Phase I/II trial in treatment of anemia via production and delivery of erythropoietin to patients with chronic kidney disease and end-stage renal disease.
    • Game plan includes in-house development of Biopump for orphan indications and potentially partnering for further development for an ESRD/CKD indication.
  • Favorable Ruling In Markman Hearing Opens Up Options For Zecotek
    Thu, May. 15 ZMSPF 13 Comments

    Summary

    • Markman Hearing - court rules in Zecotek's favor.
    • Zecotek can now move to trial.
    • Stock reacted favorably, but we still see significant upside in the shares.
  • LED Medical: Tepid Results But Substantive Progress Being Made With Turnaround Strategy
       • Thu, May. 15 LEDIF 1 Comment

    Summary

    • New Strategy To Revive Growth Recently Implemented and Showing Early Progress.
    • Recent and Near-Term Financial Results Will Likely Remain Tepid.
    • We Think Strategy Shift Begins To Make More Meaningful Financial Impact Later in 2014.
  • Revenue Hit From Loss Of Manufacturing Customer But Recent Sell-Off Overdone
       • Mon, May. 12 BLFS 7 Comments

    Summary

    • Loss of Contract Manufacturing Customer a Surprise, Results in Big Downward Revisions to Revenue Estimates.
    • But....This Was Very Low Margin and Core Business (High Margin) Is Growing At ~30%.
    • Recent Massive Sell-Off In Stock Is Overdone.
  • Turnaround Strategy Being Implemented At Competitive Technologies
       • Thu, Mar. 13 CTTC 28 Comments

    Summary

    • New CEO brought on board to orchestrate turnaround of ugly historical financial performance.
    • First orders of business; new commercialization strategy and cost-control measures.
    • Seeking FDA approval of flagship product - will be time consuming/costly but could pay big dividends.
    • We think the game plan makes sense but legacy risks remain a big hurdle.
  • iCAD Inc: Expect 2013 Revenue Momentum To Carry Through 2014
       • Sat, Feb. 22 ICAD 1 Comment
  • Righting The Ship At CryoPort
    Editors' Pick • Fri, Feb. 21 CYRX 2 Comments
  • Put Corgenix On Your Radar
       • Wed, Feb. 19 LLY, CONX 3 Comments
  • BioLife Solutions Posts Another Record Year With Revenue Up 58%
    Tue, Feb. 18 BLFS 2 Comments
  • Scrutiny Over Medical Device Safety Offers Opportunity For VeriTeQ
    Fri, Feb. 14 AGN, JNJ, VTEQ 6 Comments
  • Several Catalysts To Reignite Growth At LED Medical
       • Wed, Jan. 22 LEDIF 3 Comments
  • Zecotek, A Potential Big Winner In PET Scanner Space
       • Oct. 4, 2013 PHG, ZMSPF, SIEGY 3 Comments
  • OptimizeRx CEO Resignation A Non-Event
    Sep. 30, 2013 DVLY, AMBT, OPRX 7 Comments
  • Pharma Bio-Serv Is Low-Risk And Trading Cheap
    Sep. 16, 2013 PBSV Comment!
  • PST Launch, A New Inflection Point For Interleukin Genetics
    Editors' Pick • Jun. 21, 2013 ILIU 5 Comments
  • CryoPort's Game-Changer In Frozen Biological Shipping
       • Jun. 18, 2013 FDX, SNY, LLY 2 Comments
  • Sanuwave: DermaPACE Could Be Very Competitive In $2B Diabetic Foot Ulcer Market
       • Jun. 12, 2013 DSCI, KCI, NVS 3 Comments
  • Competitive Advantages, Huge Skin Cancer Market Bode Well For Aura
       • Jun. 5, 2013 MELA, VRSEF 14 Comments
  • OptimizeRx's SampleMD Revolutionizing Prescription Drug Sampling
    Editors' Pick • May. 22, 2013 MDRX, OPRX 3 Comments
  • BioLife Has More Room To Run
    Editors' Pick • May. 17, 2013 BLFS Comment!
  • VolitionRx Could Be A Game Changer In Cancer Detection
    Editors' Pick • May. 9, 2013 ABT, VNRX, SIEGY Comment!
  • ICAD's Double-Digit Growth Looks Sustainable
    May. 1, 2013 ICAD 10 Comments
  • Is This The Inflection Point For OptimizeRx?
    Mar. 14, 2013 OPRX 4 Comments
  • Chembio Caps 2012 With Another Revenue Record
    Mar. 12, 2013 CEMI Comment!
  • iCAD Q4 Results - Revenue Remains Strong, Expense Control Impressive
    Feb. 22, 2013 ICAD 4 Comments
  • Put Response Biomedical On Your Radar
    Feb. 3, 2013 ABT, ALR, RPBIF 4 Comments
  • Rockwell Medical: Q3 Expenses Jump, Calcitriol Launch Pushed Back Again
    Nov. 12, 2012 RMTI Comment!